;
Skip to main content
Home > The Daily Extra > Top Story

Chronological Index of : Top Story

 Current Issue
  • TOP STORY: Third Point pushes for Amgen breakup

    Activist investor Third Point on Tuesday outlined a plan for increasing the valuation of Amgen Inc. (NASDAQ:AMGN) by more than 80% in the next two years. The firm wants Amgen to split into two companies, one each for "…

    Published on 10/21/2014
  • TOP STORY: NewLink lands $150M upfront from Genentech

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) acquired exclusive, worldwide rights to cancer candidate NLG919 from NewLink Genetics Corp. (NASDAQ:NLNK) for $150 million up front. NewLink is eligible for …

    Published on 10/20/2014
  • TOP STORY: Amgen sues Sanofi, Regeneron over PCSK9

    Amgen Inc. (NASDAQ:AMGN) filed a lawsuit in the U.S. District Court for the District of Delaware alleging that alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) infringes…

    Published on 10/17/2014
  • TOP STORY: Canaan closes tenth fund at $675M

    Canaan Partners closed its tenth fund, Canaan X, with $675 million. The firm expects to invest about a third of the fund, or $225 million, in healthcare, with the rest earmarked for IT. Within healthcare, the firm plans…

    Published on 10/16/2014
  • TOP STORY: FDA accelerates approval for Esbriet, Ofev

    FDA on Wednesday approved two drugs for idiopathic pulmonary fibrosis (IPF): Esbriet pirfenidone from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Ofev nintedanib from Boehringer Ingelheim GmbH (…

    Published on 10/15/2014
  • TOP STORY: J&J vows "competitive" HCV pricing

    Johnson & Johnson CFO Dominic Caruso said the company intends to "remain competitive in the HCV category" following the approval of Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), suggesting the…

    Published on 10/14/2014
  • TOP STORY: Alnylam up on patisiran Phase II extension data

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) jumped $13.83 (19%) to $86.68 after six-month data from a Phase II study of patisiran ( ALN-TTR02) suggested the compound may have halted progression of transthyretin (TTR)-…

    Published on 10/13/2014
  • TOP STORY: FDA approves Gilead's Harvoni HCV combo

    FDA approved Harvoni ledipasvir/sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), the first oral combination therapy to treat chronic HCV genotype 1 infection that does not require interferon or ribavirin. Harvoni is …

    Published on 10/10/2014
  • TOP STORY: Achillion HCV combo has 100% SVR in Phase II

    A combination including ACH-3102 from Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) led to 100% SVR8 rates in a Phase II study to treat HCV genotype 1, according to an abstract released ahead of the American Association …

    Published on 10/9/2014
  • TOP STORY: How BMS's all-oral HCV regimen lines up

    A fixed-dose combination of daclatasvir, asunaprevir and BMS-791325 from Bristol-Myers Squibb Co. (NYSE:BMY) produced SVR12 rates of 92% in treatment-naive patients and 89% in treatment-experienced subjects in the Phase…

    Published on 10/8/2014
  • TOP STORY: BMS withdraws asunaprevir NDA

    One day prior to releasing data on regimens including its daclatasvir to treat HCV, Bristol-Myers Squibb Co. (NYSE:BMY) said it has withdrawn its NDA for asunaprevir and will no longer pursue FDA approval of a dual …

    Published on 10/7/2014
  • TOP STORY: Actavis raises stakes in ABSSSI race

    Actavis plc (NYSE:ACT) will acquire Durata Therapeutics Inc. (NASDAQ:DRTX) for $675 million in cash up front, or $23 per share, plus up to $146.5 million in regulatory and commercial milestones in the form of a …

    Published on 10/6/2014
  • TOP STORY: Salix, Cosmo abandon merger

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) and Cosmo Pharmaceuticals S.p.A. (SIX:COPN) said they have ended their merger agreement. The two companies had envisioned financial benefits from domiciling the combined entity …

    Published on 10/3/2014
  • TOP STORY: EMA adopts transparency policy

    EMA's management board unanimously adopted its clinical data transparency policy,to be introduced in two phases starting Jan. 1, 2015. In the first phase, EMA will publish clinical reports supporting MAA submissions …

    Published on 10/2/2014
  • TOP STORY: Esperion jumps on Phase IIb ETC-1002 results

    Esperion Therapeutics Inc. (NASDAQ:ESPR) said both doses of its ETC-1002 met the primary endpoint compared to ezetimibe in a Phase IIb study to treat patients with hypercholesterolemia, with or without statin …

    Published on 10/1/2014
  • TOP STORY: J&J buying Alios for $1.75B

    Johnson & Johnson (NYSE:JNJ) is acquiring Alios BioPharma Inc. (South San Francisco, Calif.) for $1.75 billion in cash. The pharma receives Alios' antiviral assets, including AL-8176 to treat respiratory syncytial virus…

    Published on 9/30/2014
  • TOP STORY: CVR boosts Ambit in Daiichi Sankyo deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568) will acquire Ambit Biosciences Corp. (NASDAQ:AMBI) for up to $410 million. The deal includes $315 million in upfront cash, or $15 per share, plus $95 million in commercial milestones…

    Published on 9/29/2014
  • TOP STORY: CHMP recommends Gilead's HCV combo

    EMA's CHMP recommended marketing authorization for Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) to treat chronic HCV infection in adults. Gilead expects a final decision from the European …

    Published on 9/26/2014
  • TOP STORY: Nicox gains on Phase III glaucoma data

    Nicox S.A. (Euronext:COX) gained EUR 0.46 (21%) to EUR 2.62 on Thursday after it said Vesneo latanoprostene bunod (formerly NCX 116, BOL-303259-X) met its primary endpoint of non-inferiority vs. timolol maleate in two …

    Published on 9/25/2014
  • TOP STORY: Acorda buying Civitas for $525M

    Neurological disorder company Acorda Therapeutics Inc. (NASDAQ:ACOR) surged $8.27 (28%) to $37.62 on Wednesday on news it will acquire Civitas Therapeutics Inc. (Chelsea, Mass.) for $525 million in cash. The main driver…

    Published on 9/24/2014
  • TOP STORY: Molecular Partners files for IPO

    Ophthalmic and cancer company Molecular Partners AG (Schlieren, Switzerland) said it is planning to raise CHF125 million ($133.1 million) in an IPO on the SIX Swiss Exchange in 4Q14. Molecular's lead compound is …

    Published on 9/23/2014
  • TOP STORY: Merck buying Sigma-Aldrich for $17B

    Merck KGaA (Xetra:MRK) will acquire Sigma-Aldrich Corp. (NASDAQ:SIAL) for about $17 billion in cash. Merck will pay $140 per share, a 37% premium to Sigma-Aldrich's Friday close of $102.37, before the news was announced…

    Published on 9/22/2014
  • TOP STORY: GSK apologizes after huge fine in China

    A Chinese court has fined the GSK China Investment Co. Ltd. subsidiary of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and found it guilty of bribing "non-government personnel" and violating Chinese law by offering money or …

    Published on 9/19/2014
  • TOP STORY: ProQR raises $97.5M in bumped up IPO

    ProQR Therapeutics N.V. (NASDAQ:PRQR) jumped $1.73 (13%) to $14.73 in its first day of trading Thursday after raising $97.5 million through the sale of 7.5 million shares at $13 in an IPO. The IPO price valued the …

    Published on 9/18/2014
  • TOP STORY: Tokai raises $92.7M in upsized IPO

    Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) was up $8.76 (58%) to $23.76 on its first day of trading Wednesday after raising $97.2 million through the sale of 6.5 million shares at $15 in an IPO. The IPO price valued the …

    Published on 9/17/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993